摘要
免疫疗法是一种快速发展的治疗自身免疫病和癌症的方法。细胞毒性T淋巴细胞抗原4(cytotoxic T lymphocyte antigen 4,CTLA-4)是适应性免疫应答的主要抑制分子,也是该领域最著名和研究最广泛的分子。CTLA-4能够通过多种机制来调节和控制免疫细胞的功能。随着对CTLA-4研究的深入,科学家已经研发出CTLA-4类似物阿巴西普和针对CTLA-4的抗体伊匹木单抗。这两种针对CTLA-4的生物制剂,在自身免疫病和肿瘤疾病的治疗中具有广阔的应用前景。
Immunotherapy is a rapidly developing treatment for autoimmune diseases and cancer.Cytotoxic T lymphocyte antigen 4(CTLA-4)is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field.CTLA-4 can regulate and control the function of immune cells through a variety of mechanisms.With further research on CTLA-4,CTLA-4-Ig abatacept and antibody against CTLA-4 ipilimumab have been developed.These two biological agents have broad application prospects in the treatment of autoimmune diseases and tumor diseases.
作者
房玉蝶
祝洁(综述)
张进安(审校)
Fang Yudie;Zhu Jie;Zhang Jin’an(Graduate School,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Depertment of Endocrinology&Rheumatology,Shanghai University of Medicine&Health Science Affiliated Zhoupu Hospital,Shanghai 201318,China;Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处
《国际生物制品学杂志》
CAS
2021年第5期276-281,共6页
International Journal of Biologicals
基金
国家自然科学基金(81873636)
上海市重点专科项目(ZK2019C09)
浦东新区卫生健康委员会卫生科研项目(PW2019D-12)
浦东新区周浦医院青年基金项目(ZPXM-2019A-02)。
